Jason Gotlib

Clinical Trials

• Phase II PKC412 in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Recruiting
• A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients Recruiting
• Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
• An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome Recruiting
• Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Recruiting
• Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Recruiting
• Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Recruiting
• Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Recruiting
• Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin Followed By High-Dose Cytarabine Followed By Either Gemtuzumab Ozogamicin or No Additional Therapy in Treating Patients With Previously Untreated De Novo Acute Myeloid Leukemia Recruiting
• Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
• Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies Recruiting
• Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Recruiting
• Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) Recruiting
• Gemtuzumab and Combination Chemothearpy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Recruiting
• Integrated Whole-Genome Analysis of Hematologic Disorders Recruiting
• Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Recruiting
• Phase I/II of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients with Acute Myeloid Leukemia Recruiting
• Phase II Intergroup Clinical Trial For Adolescents & Young Adults With Untreated ALL Recruiting
• Phase II Temozolomide in Acute Myeloid Leukemia Patient Age >= 60 Yrs & Poor Risk/Refractory Disease Recruiting
• Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease Recruiting
• Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia Recruiting
• Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL (STAR-1) Recruiting
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST) Recruiting
• Vorinostat and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Recruiting
• A Dose-Escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis No longer recruiting
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers No longer recruiting
• An Open-Label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib (Glivec®/Gleevec®) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase No longer recruiting
• Biomarker To Evaluate protein Profiles of neutropnic Fever/Infection with Acute or Chronic Leukemias No longer recruiting
• Ph I TG101348 for primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis No longer recruiting
• A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia No longer recruiting
• Determination of Safe and Effective Dose of AMG 531 in Subjects With MDS Receiving Hypomethylating Agents No longer recruiting
• Phase 1/2 Study of VELCADE®, Dexamethasone, and Revlimid® Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid in Patients With Previously Untreated Multiple Myeloma (EVOLUTION) Completed
• Study of Intravenously Administered SNS-032 in Patients With Advanced B-Lymphoid Malignancies No longer recruiting
• Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Completed